<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401609</url>
  </required_header>
  <id_info>
    <org_study_id>G-Step</org_study_id>
    <nct_id>NCT00401609</nct_id>
  </id_info>
  <brief_title>G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients</brief_title>
  <acronym>G-Step</acronym>
  <official_title>Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the activity and toxicity of gemcitabine combined
      with four different drugs (carboplatin or cisplatin or etoposide or vinorelbine) as first
      line treatment of elderly patients with extensive small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four treatment arms are planned.

        -  GEMVIN: gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on days 1 &amp; 8, every 21 days

        -  GEMCAR: gemcitabine 1000 on days 1 &amp; 8 and carboplatin AUC 3.5 or 4 or 4.5 on day 1,
           every 21 days

        -  GEMCIS: gemcitabine 1000 mg/m2 on days 1 &amp; 8 and cisplatin 50 or 60 or 70 mg/m2 on day
           1, every 21 days

        -  GEMETO: gemcitabine 1000 mg/m2 on days 1 &amp; 8 and etoposide 60 or 70 or 80 mg/m2 on days
           1,2,3 every 21 days

      For the study of the GEMVIN combination a two-stage minimax flexible design will be applied.
      For the remaining 3 combinations (GEMCAR, GEMCIS, GEMETO) a phase 1/2 design aimed at looking
      for optimal dose within a Bayesian framework will be applied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate activity and toxicity of GEMVIN combination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>to identify optimal dose of GEMETO, GEMCAR, and GEMCIS combinations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>to evaluate activity and toxicity of GEMETO, GEMCAR, and GEMCIS combinations</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment impact on patient quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic value of ADL and IADL multidimensional geriatric evaluation scales</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical variables predictive of response to treatment</measure>
  </secondary_outcome>
  <enrollment>85</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of SCLC

          -  Extensive disease

          -  Measurable disease

          -  Performance Status (ECOG) &lt; o = 2

          -  Age &gt; o = 70 years.

          -  Written informed consent.

        Exclusion Criteria:

          -  Previous chemotherapy.

          -  Previous or concomitant malignancies (with the exception of adequately treated non
             melanomatous skin cancer or carcinoma in situ of the cervix)

          -  •Neutrophils&lt;2.000/mm3;platelets&lt;100.000/mm3; hemoglobin &lt; 10 g/dl

          -  Creatinine &gt; 1.5 time the upper limit

          -  AST, ALT &gt; 2.5 times and/or bilirubin &gt; 1.5 time the upper limit of normal if liver
             metastases are absent or AST, ALT ³5 times and bilirubin &gt; 3 times the upper limit of
             normal if liver metastases are present

          -  Symptomatic brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cesare Gridelli, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Giuseppe Moscati Hospital, Avellino, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica</name>
      <address>
        <city>Monteforte Irpino</city>
        <state>AV</state>
        <zip>83024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oncologico Bari, Oncologia Medica</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Cardarelli</name>
      <address>
        <city>Campobasso</city>
        <state>CB</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mariano Santo, U.O. di Oncologia Medica</name>
      <address>
        <city>Cosenza</city>
        <state>CS</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto di Frosinone</name>
      <address>
        <city>Frosinone</city>
        <state>FR</state>
        <zip>03031</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I SS. Trinita' Ospedale</name>
      <address>
        <city>Frosinone</city>
        <state>FR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Serbelloni</name>
      <address>
        <city>Gorgonzola</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario P. Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale La ferla</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Polla</city>
        <state>SA</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica, U.S.L.L. 13</name>
      <address>
        <city>Noale</city>
        <state>VE</state>
        <zip>30033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale L. Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale 2</name>
      <address>
        <city>Pozzuoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena, Divisione di Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Camillo - Forlanini</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G-STEP Investigators. Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. J Thorac Oncol. 2012 Jan;7(1):233-42. doi: 10.1097/JTO.0b013e318233d6c2.</citation>
    <PMID>22031232</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <name_title>Francesco Perrone</name_title>
    <organization>NCI Naples</organization>
  </responsible_party>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

